Transparency
Our Methodology
How we collect, verify, and present the clinical trial data and catalyst information you see on ClinicalInvestor.
Data Collection
Our data pipeline pulls from multiple official sources to ensure accuracy and completeness. We prioritize primary sources over secondary reporting.
FDA Sources
PDUFA date letters, approval and CRL announcements, Advisory Committee calendars, and Breakthrough Therapy designations sourced directly from FDA.gov.
Clinical Trial Registries
Trial status, enrollment data, primary endpoints, and result postings from ClinicalTrials.gov and international registries.
SEC Filings
Material events (8-K), quarterly financials (10-Q), annual reports (10-K), and prospectuses (S-1) for pipeline and financial context.
Company Disclosures
Press releases, investor presentations, earnings call transcripts, and conference poster and oral presentation abstracts.
Verification Process
Every catalyst date and data point goes through a multi-step verification process before appearing on the site.
Primary source identification: We locate the official source document for every data point.
Cross-reference check: Dates and facts are verified against at least one additional source.
Ongoing monitoring: Published data is continuously monitored for updates, corrections, and changes.
Limitations
PDUFA dates can be extended or changed by the FDA without public notice. Clinical trial timelines are estimates that frequently shift.
ClinicalInvestor is an educational tool, not a substitute for professional financial advice. Always verify critical information through primary sources before making investment decisions.
Corrections
Found an error? Contact us at corrections@clinicalinvestor.com.